The Market Reports

Synopsis
The global market for Pet Pharmaceuticals was estimated to be worth US$ 17510 million in 2024 and is forecast to a readjusted size of US$ 28170 million by 2031 with a CAGR of 7.0% during the forecast period 2025-2031.
Pet pharmaceutical refers specifically to medicines given to pets. In terms of the purpose of use, pet drugs are mainly used by dogs and cats. Through drug prevention and treatment of pet diseases, the cure rate of pet diseases can be improved, the physical and mental health of pets can be guaranteed, and the quality of life of pets can be improved. In terms of clinical significance, the application of pet drugs can provide clinical data for the research and development of new pet drugs, and promote the replacement and upgrading of new pet drugs.
The pet pharmaceuticals market is experiencing strong growth, driven by the rising trend of pet humanization, increasing pet ownership, and heightened awareness of animal health. As more people consider pets as part of the family, spending on veterinary care and pharmaceuticals has surged globally. Advancements in veterinary medicine have also contributed to the development of more targeted and effective drugs for chronic diseases, pain management, parasitic infections, and preventive care. Additionally, the growing elderly population and single households have led to higher demand for companion animals, further fueling the market. Pet insurance is becoming more widespread, especially in North America and Europe, making veterinary drugs more accessible and affordable to pet owners. These factors collectively boost the demand for both prescription and over-the-counter pet medications.
Despite promising growth, the pet pharmaceuticals market faces several challenges. Regulatory requirements for veterinary drugs are becoming stricter, increasing the time and cost needed for product development and approval. Additionally, counterfeit and low-quality medications, particularly in developing regions, can undermine the trust of veterinarians and pet owners. Limited availability of skilled veterinary professionals in some countries also affects the diagnosis and prescription of appropriate pharmaceutical treatments. Another barrier is the high cost of innovative pet drugs, which can deter adoption, especially among lower-income pet owners. Moreover, competition from alternative therapies and natural remedies is rising, presenting additional challenges for pharmaceutical companies to differentiate their products in an increasingly crowded marketplace.
The major players in global Pet Pharmaceuticals market include Zoetis, Boehringer Ingelheim, Merck, etc. The top 3 players occupy about 60% shares of the global market. North America and Europe are main markets, they occupy about 80% of the global market. Antiparasitic is the main type, with a share about 30%. Prevention is the main application, which holds a share about 80%.
This report aims to provide a comprehensive presentation of the global market for Pet Pharmaceuticals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pet Pharmaceuticals by region & country, by Type, and by Application.
The Pet Pharmaceuticals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet Pharmaceuticals.
Market Segmentation
By Company
Zoetis
Boehringer Ingelheim
Merck
Elanco
Virbac
Dechra Veterinary Products
Ceva
Vetoquinol
Ouro Fino Saude
Norbrook
Jindun
Chopperlvya Animal Health
CAHIC
Animalcare Group
Parnell
Ringpu
Jinyu Group
Kyoritsu Seiyaku
Segment by Type
Antiparasitic
Biological Products
Antibacterial
Others
Segment by Application
Prevention
Treatment
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pet Pharmaceuticals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pet Pharmaceuticals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pet Pharmaceuticals in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index